EX-99.1 2 zbh-ex991_6.htm EX-99.1 zbh-ex991_6.htm

 

Exhibit 99.1


 

345 E. Main St.

 

Warsaw, IN 46580

 

www.zimmerbiomet.com

 

 

 

Media

Investors

Monica Kendrick

Matt Abernethy

574-372-4989

574-371-8042

monica.kendrick@zimmerbiomet.com

matt.abernethy@zimmerbiomet.com

 

 

 

Barbara Goslee

 

574-371-9449

 

barb.goslee@zimmerbiomet.com  

 

Zimmer Biomet Reports Third Quarter

2017 Financial Results

 

 

Net sales of $1.818 billion for the third quarter represent a decrease of 0.8% from the prior year period, and a decrease of 1.2% on a constant currency basis

 

Diluted EPS for the third quarter were $0.48, a decrease of 38.5% from the prior year period

 

Adjusted diluted EPS for the third quarter were $1.72, a decrease of 3.9% from the prior year period

 

The Company updates 2017 sales and earnings guidance

(WARSAW, IN) November 1, 2017 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2017.  The Company reported third quarter net sales of $1.818 billion, a decrease of 0.8% from the prior year period, and a decrease of 1.2% on a constant currency basis.  Excluding approximately 30 basis points of contribution from the LDR Holding Corporation

Page 1


 

acquisition, third quarter 2017 revenues decreased 1.1% from the third quarter of 2016, or 1.5% on a constant currency basis.

Diluted earnings per share for the quarter were $0.48, a decrease of 38.5% from the prior year period.  Adjusted diluted earnings per share for the quarter were $1.72, a decrease of 3.9% from the prior year period.

“Our top line results remained challenged during the third quarter, due to the pace of supply recovery of certain key brands and the related impact on sales recapture, particularly in the United States.  Our sales were also impacted by the price action taken by the government of India and by softened domestic market conditions, including the effect of the hurricanes on third quarter procedural volumes,” said Daniel P. Florin, Interim Chief Executive Officer, Senior Vice President and Chief Financial Officer of Zimmer Biomet. “While we are not satisfied with our overall performance during the quarter, we remain confident in the underlying market, as well as the Company's sales forces, the breadth of our portfolio and our strategic innovation pipeline. Looking forward, our global teams will continue to make progress towards increasing supply availability and enabling improved commercial execution.”

Net earnings for the third quarter were $98.8 million, a decrease of 37.8% from the prior year period, and $349.9 million on an adjusted basis, a decrease of 3.4% from the prior year period.  Operating cash flow for the third quarter was $455.1 million.

In the quarter, the Company paid $48.5 million in dividends and declared a third quarter dividend of $0.24 per share.  The Company has repaid approximately $950 million of debt year-to-date in 2017.

Guidance

The Company is updating its full-year 2017 constant currency revenue and adjusted earnings per share guidance.  For the full year, the Company now expects revenue in the range of $7.76 billion to $7.80 billion, representing growth of 1.0% to 1.5% compared to the prior year and constant currency revenue growth of 0.9% to 1.4% compared to the prior year, inclusive of approximately 120 basis points of contribution from the LDR transaction.  Previously, the Company had expected full-year, constant currency revenue growth between 1.8% and 2.7%, inclusive of approximately 120 basis points of

Page 2


 

contribution from the LDR transaction.  Additionally, the Company now expects its full-year 2017 diluted earnings per share to be in a range of $3.80 to $3.93, and in a range of $8.01 to $8.07 on an adjusted basis.  Previously, the Company had expected full-year 2017 diluted earnings per share to be in a range of $4.15 to $4.35, and in a range of $8.20 to $8.30 on an adjusted basis.

For the fourth quarter of 2017, the Company expects revenue in the range of $2.01 billion to $2.05 billion, representing growth of 0% to positive 2.0% compared to the prior year period and constant currency revenue growth of negative 1.8% to positive 0.2% compared to the prior year period.  Additionally, the Company expects its diluted earnings per share for the fourth quarter to be in a range of $0.94 to $1.08, and in a range of $2.08 to $2.14 on an adjusted basis.

Conference Call and Earnings Release Information

The Company will conduct its third quarter 2017 investor conference call today, November 1, 2017 at 8:00 a.m. Eastern Time.  The audio webcast and earnings release information, including the Company’s third quarter investor presentation, can be accessed via Zimmer Biomet’s Investor Relations website at http://investor.zimmerbiomet.com.  The audio webcast will be archived for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 312-9837 and entering conference ID 7278985.  For a complete listing of international toll-free and local numbers, please visit http://investor.zimmerbiomet.com.  A digital recording will be available 24 hours after the completion of the conference call, from November 2, 2017 to December 1, 2017.  To access the recording, U.S. callers should dial (888) 203-1112 and international callers should dial +1 (719) 457-0820, and enter the Access Code ID 7278985.

Sales Tables

The following sales tables provide results by geography and product category, as well as the percentage change compared to the prior year quarter and nine months, on both a reported and a constant currency basis.  

Page 3


 

NET SALES - THREE MONTHS ENDED SEPTEMBER 30, 2017

(in millions, unaudited)

 

 

 

 

 

 

 

 

 

 

Constant

 

 

 

Net

 

 

 

 

 

 

 

Currency

 

 

 

Sales

 

 

% Change

 

 

 

% Change

 

 

Geographic Results

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

$

1,142

 

 

 

(2.9

)

%

 

 

(3.0

)

%

EMEA

 

381

 

 

 

3.3

 

 

 

 

(0.4

)

 

Asia Pacific

 

295

 

 

 

2.4

 

 

 

 

5.2

 

 

Total

$

1,818

 

 

 

(0.8

)

%

 

 

(1.2

)

%

Product Categories

 

 

 

 

 

 

 

 

 

 

 

 

 

Knees

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

$

383

 

 

 

(3.8

)

%

 

 

(3.9

)

%

EMEA

 

135

 

 

 

3.7

 

 

 

 

0.6

 

 

Asia Pacific

 

106

 

 

 

2.3

 

 

 

 

3.9

 

 

Total

 

624

 

 

 

(1.2

)

 

 

 

(1.7

)

 

Hips

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

228

 

 

 

(4.5

)

 

 

 

(4.7

)

 

EMEA

 

115

 

 

 

2.4

 

 

 

 

(1.5

)

 

Asia Pacific

 

91

 

 

 

2.1

 

 

 

 

6.1

 

 

Total

 

434

 

 

 

(1.4

)

 

 

 

(1.7

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.E.T (1)

 

407

 

 

 

1.2

 

 

 

 

1.1

 

 

Dental

 

93

 

 

 

(3.2

)

 

 

 

(4.4

)

 

Spine & CMF

 

185

 

 

 

0.7

 

 

 

 

0.3

 

 

Other

 

75

 

 

 

(4.8

)

 

 

 

(5.3

)

 

Total

$

1,818

 

 

 

(0.8

)

%

 

 

(1.2

)

%

 

(1)

Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

Page 4


 

NET SALES - NINE MONTHS ENDED SEPTEMBER 30, 2017

(in millions, unaudited)

 

 

 

 

 

 

 

 

 

Constant

 

 

 

Net

 

 

 

 

 

 

Currency

 

 

 

Sales

 

 

% Change

 

 

% Change

 

 

Geographic Results

 

 

 

 

 

 

 

 

 

 

 

 

Americas

$

3,586

 

 

 

1.5

 

%

 

1.4

 

%

EMEA

 

1,272

 

 

 

(1.0

)

 

 

0.4

 

 

Asia Pacific

 

892

 

 

 

4.8

 

 

 

6.0

 

 

Total

$

5,750

 

 

 

1.4

 

%

 

1.8

 

%

Product Categories

 

 

 

 

 

 

 

 

 

 

 

 

Knees

 

 

 

 

 

 

 

 

 

 

 

 

Americas

$

1,217

 

 

 

(2.2

)

%

 

(2.2

)

%

EMEA

 

463

 

 

 

(2.2

)

 

 

(0.1

)

 

Asia Pacific

 

326

 

 

 

3.5

 

 

 

3.8

 

 

Total

 

2,006

 

 

 

(1.3

)

 

 

(0.8

)

 

Hips

 

 

 

 

 

 

 

 

 

 

 

 

Americas

$

720

 

 

 

(1.9

)

 

 

(1.9

)

 

EMEA

 

382

 

 

 

(1.5

)

 

 

(0.6

)

 

Asia Pacific

 

278

 

 

 

5.3

 

 

 

7.2

 

 

Total

 

1,380

 

 

 

(0.4

)

 

 

0.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.E.T (1)

 

1,255

 

 

 

3.3

 

 

 

3.7

 

 

Dental

 

311

 

 

 

(3.5

)

 

 

(3.4

)

 

Spine & CMF

 

565

 

 

 

20.1

 

 

 

20.1

 

 

Other

 

233

 

 

 

(4.9

)

 

 

(4.5

)

 

Total

$

5,750

 

 

 

1.4

 

%

 

1.8

 

%

 

(1)

Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

 

Page 5


 

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.  

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the “Investor Relations” section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).  These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Sales change information for the three- and nine-month periods ended September 30, 2017 is presented on a GAAP (reported) basis and on a constant currency basis, as well as on a basis that excludes the contribution from the Company's acquisition of LDR Holding Corporation in July 2016.  Projected revenue change information is also presented on a GAAP basis and on a constant currency basis.  Constant currency rates exclude the effects of foreign currency exchange rates.  They are calculated by translating current and prior-period sales at the same

Page 6


 

predetermined exchange rate.  The translated results are then used to determine year-over-year percentage increases or decreases.  Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in this press release.

Net earnings, diluted earnings per share and projected diluted earnings per share are presented on a GAAP (reported) basis and on an adjusted basis.  Adjusted earnings and adjusted diluted earnings per share exclude the effects of inventory step-up; certain inventory and manufacturing-related charges connected to discontinuing certain product lines, quality enhancement and remediation efforts; special items; intangible asset amortization; any related effects on our income tax provision associated with these items; and other certain tax adjustments.  Special items include expenses resulting directly from our business combinations and/or global restructuring, quality and operational excellence initiatives, including employee termination benefits, certain contract terminations, consulting and professional fees, dedicated project personnel, asset impairment or loss on disposal charges, certain litigation matters, costs of complying with our deferred prosecution agreement and other items.  Other certain tax adjustments include a tax restructuring that lowered the tax rate on deferred tax liabilities recorded on intangible assets recognized in acquisition-related accounting, net favorable resolutions of various tax matters, and charges from internal restructuring transactions that provide the Company access to cash in a tax efficient manner.

Management uses these non-GAAP financial measures internally to evaluate the performance of the business and believes they are useful measures that provide meaningful supplemental information to investors to consider when evaluating the performance of the Company.  Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported operating results, to perform trend analysis, to better identify operating trends that may otherwise be masked or distorted by these types of items and to provide additional transparency of certain items.  In addition, certain of these non-GAAP financial measures are used as performance metrics in the Company's incentive compensation programs.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding sales and earnings guidance and any statements about our expectations, plans, strategies or prospects.  We generally use the words “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “sees,” “seeks,” “should,” “could,” “intends” and similar expressions to identify forward-looking statements.  Such statements are based upon the current beliefs and expectations of

Page 7


 

management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially.  These risks, uncertainties and changes in circumstances include, but are not limited to: our chief executive officer transition, including disruptions and uncertainties related thereto, our ability to appoint a permanent successor with the desired level of experience and expertise in a timely manner, the potential impact on our business and future strategic direction resulting from our transition to a new chief executive officer, and our ability to retain other key members of senior management; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management’s attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, vendors and lenders and on our operating results and businesses generally; compliance with the Deferred Prosecution Agreement entered into in January 2017; the success of our quality and operational excellence initiatives, including ongoing quality enhancement and remediation efforts at the legacy Biomet Warsaw facility; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration (FDA) and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the ability to remediate matters identified in any inspectional observations or warning letters issued by the FDA, while continuing to satisfy the demand for our products; the outcome of government investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability and intellectual property litigation losses; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries.  For

Page 8


 

a further list and description of such risks and uncertainties, see our reports filed with the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2016 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.  Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.zimmerbiomet.com or on request from us.  Forward-looking statements speak only as of the date they are made, and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this release.

###

Page 9


 

ZIMMER BIOMET HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, except per share amounts, unaudited)

 

 

2017

 

 

2016

 

Net Sales

$

1,818.1

 

 

$

1,832.8

 

Cost of products sold, excluding intangible asset amortization

 

500.9

 

 

 

479.3

 

Intangible asset amortization

 

152.7

 

 

 

164.3

 

Research and development

 

91.2

 

 

 

95.6

 

Selling, general and administrative

 

694.5

 

 

 

727.7

 

Special items

 

165.4

 

 

 

170.4

 

Operating expenses

 

1,604.7

 

 

 

1,637.3

 

Operating Profit

 

213.4

 

 

 

195.5

 

Other expense, net

 

(4.5

)

 

 

(1.1

)

Interest income

 

0.6

 

 

 

0.6

 

Interest expense

 

(82.3

)

 

 

(91.5

)

Earnings before income taxes

 

127.2

 

 

 

103.5

 

Provision (benefit) for income taxes

 

28.4

 

 

 

(54.4

)

Net Earnings

 

98.8

 

 

 

157.9

 

Less: Net Loss attributable to noncontrolling interest

 

-

 

 

 

(0.9

)

Net Earnings of Zimmer Biomet Holdings, Inc.

$

98.8

 

 

$

158.8

 

Earnings Per Common Share

 

 

 

 

 

 

 

Basic

$

0.49

 

 

$

0.79

 

Diluted

$

0.48

 

 

$

0.78

 

Weighted Average Common Shares Outstanding

 

 

 

 

 

 

 

Basic

 

202.3

 

 

 

200.1

 

Diluted

 

204.0

 

 

 

202.9

 

Cash Dividends Declared Per Common Share

$

0.24

 

 

$

0.24

 

 

Page 10


 

ZIMMER BIOMET HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, except per share amounts, unaudited)

 

 

2017

 

 

2016

 

Net Sales

$

5,749.8

 

 

$

5,670.8

 

Cost of products sold, excluding intangible asset amortization

 

1,541.5

 

 

 

1,760.0

 

Intangible asset amortization

 

452.4

 

 

 

424.7

 

Research and development

 

272.4

 

 

 

269.9

 

Selling, general and administrative

 

2,203.3

 

 

 

2,176.6

 

Special items

 

434.1

 

 

 

397.0

 

Operating expenses

 

4,903.7

 

 

 

5,028.2

 

Operating Profit

 

846.1

 

 

 

642.6

 

Other expense, net

 

(11.2

)

 

 

(8.7

)

Interest income

 

1.4

 

 

 

2.7

 

Interest expense

 

(247.5

)

 

 

(267.8

)

Earnings before income taxes

 

588.8

 

 

 

368.8

 

Provision for income taxes

 

6.6

 

 

 

133.9

 

Net Earnings

 

582.2

 

 

 

234.9

 

Less: Net Loss attributable to noncontrolling interest

 

(0.2

)

 

 

(1.4

)

Net Earnings of Zimmer Biomet Holdings, Inc.

$

582.4

 

 

$

236.3

 

Earnings Per Common Share

 

 

 

 

 

 

 

Basic

$

2.89

 

 

$

1.18

 

Diluted

$

2.86

 

 

$

1.17

 

Weighted Average Common Shares Outstanding

 

 

 

 

 

 

 

Basic

 

201.7

 

 

 

199.9

 

Diluted

 

203.6

 

 

 

202.3

 

Cash Dividends Declared Per Common Share

$

0.72

 

 

$

0.72

 

 

Page 11


 

ZIMMER BIOMET HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

480.8

 

 

$

634.1

 

Receivables, net

 

 

1,318.5

 

 

 

1,604.4

 

Inventories

 

 

2,084.2

 

 

 

1,959.4

 

Other current assets

 

 

549.8

 

 

 

465.7

 

Total current assets

 

 

4,433.3

 

 

 

4,663.6

 

Property, plant and equipment, net

 

 

2,048.6

 

 

 

2,037.9

 

Goodwill

 

 

10,904.9

 

 

 

10,643.9

 

Intangible assets, net

 

 

8,464.9

 

 

 

8,785.4

 

Other assets

 

 

565.8

 

 

 

553.6

 

Total Assets

 

$

26,417.5

 

 

$

26,684.4

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities

 

$

1,785.2

 

 

$

1,805.9

 

Current portion of long-term debt

 

 

1,225.0

 

 

 

575.6

 

Other long-term liabilities

 

 

3,757.4

 

 

 

3,967.2

 

Long-term debt

 

 

9,199.7

 

 

 

10,665.8

 

Stockholders' equity

 

 

10,450.2

 

 

 

9,669.9

 

Total Liabilities and Stockholders' Equity

 

$

26,417.5

 

 

$

26,684.4

 

 

Page 12


 

ZIMMER BIOMET HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)

 

 

 

2017

 

 

2016

 

Cash flows provided by (used in) operating activities

 

 

 

 

 

 

 

 

Net earnings

 

$

582.2

 

 

$

234.9

 

Depreciation and amortization

 

 

798.2

 

 

 

787.3

 

Share-based compensation

 

 

40.1

 

 

 

45.9

 

Goodwill and intangible asset impairment

 

 

59.5

 

 

 

28.0

 

Inventory step-up

 

 

32.2

 

 

 

300.9

 

Changes in operating assets and liabilities, net of acquired assets and liabilities

 

 

 

 

 

 

 

 

Income taxes

 

 

(245.4

)

 

 

(125.4

)

Receivables

 

 

349.7

 

 

 

(80.3

)

Inventories

 

 

(123.2

)

 

 

44.2

 

Accounts payable and accrued expenses

 

 

(173.6

)

 

 

(76.0

)

Other assets and liabilities

 

 

(140.3

)

 

 

(154.5

)

Net cash provided by operating activities

 

 

1,179.4

 

 

 

1,005.0

 

Cash flows provided by (used in) investing activities

 

 

 

 

 

 

 

 

Additions to instruments

 

 

(255.7

)

 

 

(251.3

)

Additions to other property, plant and equipment

 

 

(109.8

)

 

 

(130.1

)

Purchases of investments

 

 

-

 

 

 

(1.4

)

Sales of investments

 

 

-

 

 

 

273.3

 

LDR acquisition, net of acquired cash

 

 

-

 

 

 

(1,021.1

)

Business combination investments, net of acquired cash

 

 

(4.0

)

 

 

(421.9

)

Other investing activities

 

 

(13.1

)

 

 

7.8

 

Net cash used in investing activities

 

 

(382.6

)

 

 

(1,544.7

)

Cash flows provided by (used in) financing activities

 

 

 

 

 

 

 

 

Proceeds from multicurrency revolving facility

 

 

400.0

 

 

 

-

 

Payments on multicurrency revolving facility

 

 

(400.0

)

 

 

-

 

Redemption of senior notes

 

 

(500.0

)

 

 

-

 

Proceeds from term loan

 

 

192.7

 

 

 

750.0

 

Payments on term loan

 

 

(640.0

)

 

 

(700.0

)

Net payments on other debt

 

 

(0.9

)

 

 

(33.1

)

Dividends paid to stockholders

 

 

(145.0

)

 

 

(140.3

)

Proceeds from employee stock compensation plans

 

 

132.6

 

 

 

113.5

 

Business combination contingent consideration payments

 

 

(9.1

)

 

 

-

 

Restricted stock witholdings

 

 

(7.6

)

 

 

(5.3

)

Debt issuance costs

 

 

(0.3

)

 

 

(3.4

)

Repurchase of common stock

 

 

-

 

 

 

(415.5

)

Net cash used in financing activities

 

 

(977.6

)

 

 

(434.1

)

Effect of exchange rates on cash and cash equivalents

 

 

27.5

 

 

 

(10.2

)

Decrease in cash and cash equivalents

 

 

(153.3

)

 

 

(984.0

)

Cash and cash equivalents, beginning of period

 

 

634.1

 

 

 

1,459.3

 

Cash and cash equivalents, end of period

 

$

480.8

 

 

$

475.3

 

 

Page 13


 

ZIMMER BIOMET HOLDINGS, INC.

NET SALES BY GEOGRAPHY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)

 

 

 

Three Months Ended September 30,

 

 

 

Nine Months Ended September 30,

 

 

 

 

2017

 

 

2016

 

 

% Inc /

(Dec)

 

 

 

2017

 

 

2016

 

 

% Inc /

(Dec)

 

 

Americas

 

$

1,142.0

 

 

$

1,175.9

 

 

 

(2.9

)

%

 

$

3,585.6

 

 

$

3,534.1

 

 

 

1.5

 

%

EMEA

 

 

381.1

 

 

 

368.8

 

 

 

3.3

 

 

 

 

1,272.5

 

 

 

1,286.0

 

 

 

(1.0

)

 

Asia Pacific

 

 

295.0

 

 

 

288.1

 

 

 

2.4

 

 

 

 

891.7

 

 

 

850.7

 

 

 

4.8

 

 

Total

 

$

1,818.1

 

 

$

1,832.8

 

 

 

(0.8

)

%

 

$

5,749.8

 

 

$

5,670.8

 

 

 

1.4

 

%

 

ZIMMER BIOMET HOLDINGS, INC.

NET SALES BY PRODUCT CATEGORY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)

 

 

 

Three Months Ended September 30,

 

 

 

Nine Months Ended September 30,

 

 

 

 

2017

 

 

2016

 

 

% Inc /

(Dec)

 

 

 

2017

 

 

2016

 

 

% Inc /

(Dec)

 

 

Knees

 

$

623.7

 

 

$

631.5

 

 

 

(1.2

)

%

 

$

2,005.9

 

 

$

2,031.7

 

 

 

(1.3

)

%

Hips

 

 

434.5

 

 

 

440.6

 

 

 

(1.4

)

 

 

 

1,380.0

 

 

 

1,385.7

 

 

 

(0.4

)

 

S.E.T

 

 

406.6

 

 

 

401.8

 

 

 

1.2

 

 

 

 

1,254.5

 

 

 

1,215.0

 

 

 

3.3

 

 

Dental

 

 

92.9

 

 

 

95.9

 

 

 

(3.2

)

 

 

 

311.1

 

 

 

322.5

 

 

 

(3.5

)

 

Spine & CMF

 

 

184.9

 

 

 

183.7

 

 

 

0.7

 

 

 

 

565.2

 

 

 

470.7

 

 

 

20.1

 

 

Other

 

 

75.5

 

 

 

79.3

 

 

 

(4.8

)

 

 

 

233.1

 

 

 

245.2

 

 

 

(4.9

)

 

Total

 

$

1,818.1

 

 

$

1,832.8

 

 

 

(0.8

)

%

 

$

5,749.8

 

 

$

5,670.8

 

 

 

1.4

 

%

 

Page 14


 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF REPORTED NET SALES % CHANGE TO

CONSTANT CURRENCY % CHANGE AND

% CHANGE EXCLUDING LDR HOLDING CORPORATION

(unaudited)

 

 

For the Three Months Ended

 

 

 

September 30, 2017

 

 

 

 

 

 

 

 

Foreign

 

 

 

Constant

 

 

 

 

 

 

 

 

Exchange

 

 

 

Currency

 

 

 

% Change

 

 

 

Impact

 

 

 

% Change

 

 

Geographic Results

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

(2.9

)

%

 

 

0.1

 

%

 

 

(3.0

)

%

EMEA

 

3.3

 

 

 

 

3.7

 

 

 

 

(0.4

)

 

Asia Pacific

 

2.4

 

 

 

 

(2.8

)

 

 

 

5.2

 

 

Total

 

(0.8

)

%

 

 

0.4

 

%

 

 

(1.2

)

%

Product Categories

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Knees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

(3.8

)

%

 

 

0.1

 

%

 

 

(3.9

)

%

EMEA

 

3.7

 

 

 

 

3.1

 

 

 

 

0.6

 

 

Asia Pacific

 

2.3

 

 

 

 

(1.6

)

 

 

 

3.9

 

 

Total

 

(1.2

)

 

 

 

0.5

 

 

 

 

(1.7

)

 

Hips

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

(4.5

)

 

 

 

0.2

 

 

 

 

(4.7

)

 

EMEA

 

2.4

 

 

 

 

3.9

 

 

 

 

(1.5

)

 

Asia Pacific

 

2.1

 

 

 

 

(4.0

)

 

 

 

6.1

 

 

Total

 

(1.4

)

 

 

 

0.3

 

 

 

 

(1.7

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.E.T

 

1.2

 

 

 

 

0.1

 

 

 

 

1.1

 

 

Dental

 

(3.2

)

 

 

 

1.2

 

 

 

 

(4.4

)

 

Spine & CMF

 

0.7

 

 

 

 

0.4

 

 

 

 

0.3

 

 

Other

 

(4.8

)

 

 

 

0.5

 

 

 

 

(5.3

)

 

Total

 

(0.8

)

%

 

 

0.4

 

%

 

 

(1.2

)

%

Impact of additional LDR Holding Corporation

    billing days in the 2017 period

 

(0.3

)

 

 

 

-

 

 

 

 

(0.3

)

 

% Change excluding LDR Holding Corporation

 

(1.1

)

%

 

 

0.4

 

%

 

 

(1.5

)

%

 

Page 15


 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF REPORTED NET SALES % CHANGE TO

CONSTANT CURRENCY % CHANGE AND

% CHANGE EXCLUDING LDR HOLDING CORPORATION

(unaudited)

 

 

 

For the Nine Months Ended

 

 

 

September 30, 2017

 

 

 

 

 

 

 

 

Foreign

 

 

 

Constant

 

 

 

 

 

 

 

 

Exchange

 

 

 

Currency

 

 

 

% Change

 

 

 

Impact

 

 

 

% Change

 

 

Geographic Results

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

1.5

 

%

 

 

0.1

 

%

 

 

1.4

 

%

EMEA

 

(1.0

)

 

 

 

(1.4

)

 

 

 

0.4

 

 

Asia Pacific

 

4.8

 

 

 

 

(1.2

)

 

 

 

6.0

 

 

Total

 

1.4

 

%

 

 

(0.4

)

%

 

 

1.8

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product Categories

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Knees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

(2.2

)

%

 

 

-

 

%

 

 

(2.2

)

%

EMEA

 

(2.2

)

 

 

 

(2.1

)

 

 

 

(0.1

)

 

Asia Pacific

 

3.5

 

 

 

 

(0.3

)

 

 

 

3.8

 

 

Total

 

(1.3

)

 

 

 

(0.5

)

 

 

 

(0.8

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hips

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Americas

 

(1.9

)

 

 

 

-

 

 

 

 

(1.9

)

 

EMEA

 

(1.5

)

 

 

 

(0.9

)

 

 

 

(0.6

)

 

Asia Pacific

 

5.3

 

 

 

 

(1.9

)

 

 

 

7.2

 

 

Total

 

(0.4

)

 

 

 

(0.6

)

 

 

 

0.2